19 November 2021: Original Paper
Diagnostic Utility of Presepsin in Infections After Liver Transplantation: A Preliminary Study
Takahiro Yokose 1ABCDEF* , Masashi Takeuchi 1ABCDEF* , Hideaki Obara 1ACDEFG* , Masahiro Shinoda 2ADF , Hirofumi Kawakubo 1ADF , Minoru Kitago 1BCD , Hiroshi Yagi 1BCD , Yuta Abe 1BCD , Yohei Yamada 1BCD , Kentaro Matsubara 1BCD , Go Oshima 1BCD , Shutaro Hori 1BCD , Takumi Fujimura 1BCD , Ryo Takemura 3CD , Ryota Ishii 3CD , Tatsuo Kuroda 1A , Yuko Kitagawa 1AGDOI: 10.12659/AOT.933774
Ann Transplant 2021; 26:e933774
Table 5 Comparison of patient characteristics between high and low preoperative levels of presepsin.
| Variables, (%) | Preoperative high (n=5) | Preoperative low (n=8) | p |
|---|---|---|---|
| Recipient age, years* | 42 (38–55) | 46 (41–51) | 0.833 |
| Body mass index, kg/m* | 19.8 (18.3–26.8) | 21.2 (19.4–22.9) | 0.943 |
| Sex, Male / Female | 1 (20.0) / 4 (80.0) | 3 (37.5) / 5 (62.5) | 0.506 |
| ASA-PS, 2 / 3 / 4 | 0 / 2 (40.0) / 3 (60.0) | 2 (25.0) / 5 (62.5) / 1 (12.5) | 0.150 |
| ECOG-PS, 0–1 / 2–3 | 0 / 5 (100) | 5 (62.5) / 3 (37.5) | 0.024 |
| Primary disease | |||
| Alcohol-related liver disease | 0 | 4 (50.0) | |
| Primary biliary cholangitis | 3 (60.0) | 0 | |
| Primary sclerosing cholangitis6 | 2 (40.0) | 0 | |
| Autoimmune hepatitis | 0 | 2 (25.0) | |
| Hepatopulmonary syndrome | 0 | 1 (12.5) | |
| Unknown | 0 | 1 (12.5) | |
| Child-Pugh score* | 12 (11–13) | 12 (10–13) | 0.622 |
| MELD score* | 33 (32–36) | 21 (16–26) | 0.011 |
| Creatinine clearance* | 35.7 (32.1–98.5) | 74.6 (64.7–96.0) | 0.284 |
| Donor type | |||
| Living / Deceased | 1 (20.0) / 4 (80.0) | 6 (75.0) / 2 (25.0) | 0.053 |
| Donor Age, years* | 44 (42–52) | 44 (29–49) | 0.833 |
| ABO blood type | |||
| Identical / Compatible / Incompatible | 3 (60.0) / 2 (40.0) / 0 | 6 (75.0) / 0 / 2 (25.0) | 0.224 |
| Intraoperative bleeding, ml* | 5390 (3295–5583) | 2273 (984–3467) | 0.284 |
| Operation time, min* | 708 (600–774) | 876 (737–917) | 0.354 |
| Bile duct reconstruction | |||
| Hepaticocholedochostomy / Hepaticojejunostomy | 3 (60.0) / 2 (40.0) | 8 (100.0) / 0 | 0.052 |
| Postoperative acute kidney injury | 4 (80.0) | 5 (62.5) | 0.506 |
| Postoperative continuous renal replacement therapy | 2 (40.0) | 2 (25.0) | 0.569 |
| * Median (25–75 percentiles). ASA – American Society of Anesthesiologists; PS – performance status; ECOG – Eastern Cooperative Oncology Group; MELD – model for end-stage liver disease. | |||